
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.

Gilead’s Tropics readout makes investors sweat
Tropics-02 reads out positively, but on the question of clinical relevance Gilead’s silence is deafening.

Enhertu tightens its stranglehold
The Astra/Daiichi antibody-drug conjugate could eat into Roche’s breast cancer dominance, courtesy of a clinical hit in Her2-low disease.

Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.

Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.

Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.